个人简介

Dr. Hendrix is a Professor of Medicine and Pharmacology and Molecular Sciences at the Johns Hopkins University School of Medicine. He has 28 years of experience in the design and conduct of translational clinical pharmacology studies, mostly of antiretroviral drugs for HIV treatment and prevention. He is the Wellcome Professor and Director, Division of Clinical Pharmacology and Director of the Drug Development Unit in the Division. His research focuses on development of antiretroviral drugs to prevent HIV infection. His HIV prevention research has been supported by CDC, NIH, USAID, the Bill and Melinda Gates Foundation, amfAR, and sponsors in the pharmaceutical industry. Dr. Hendrix received his undergraduate degree in Applied Biology at MIT (1978) and his medical degree from Georgetown University, magna cum laude (1984). He completed internship and residency in internal medicine on the Osler Medical Service, and fellowships in Infectious Diseases and Clinical Pharmacology at The Johns Hopkins Hospital. Before joining the Hopkins medical school faculty, Dr. Hendrix served on active duty for 10 years in the U.S. Air Force (USAF). Dr. Hendrix was appointed as the Wellcome Professor and Director, Division of Clinical Pharmacology in January 2015. Established in 1954, the Division of Clinical Pharmacology at The Johns Hopkins University School of Medicine is the oldest in the US and has a long history of laboratory and clinical research, teaching, and service activities. Mentoring and teaching medical students, graduate students, and post-doctoral fellows have long been his passion and integral to the success of his own research accomplishments. American Board of Internal Medicine (1987) American Board if Internal Medicine - Infectious Diseases (1990) The Johns Hopkins Hospital Osler Medical Service, Baltimore, MD, 1987, Internal Medicine Residency; Johns Hopkins University School of Medicine, Baltimore, MD, 1989, Infectious Diseases, Clinical Pharmacology

研究领域

查看导师新发文章 （温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Chemoprevention of HIV infection; Drug interactions; Clinical pharmacology of antiviral drugs; Topical HIV microbicides

Dr. Hendrix's primary research focus is chemoprevention of HIV infection. This involves oral, topical, and injectable HIV microbicide development. He conducts small, intensive sampling studies of PK and PD of drugs for HIV prevention with a focus on developing methods to better understand HIV and drug distribution in the male genital tract, female genital tract and lower gastrointestinal tract.  He also supports numerous HIV pre-exposure prophylaxis development studies from phase I to phase III, largely as leader of the Pharmacology Core Laboratory of both the Microbicide Trial Network and HIV PRevnetion Trials Network.